FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SLANSKY RICHARD B 		2. Issuer Name and Ticker or Trading Symbol

ONCOSEC MEDICAL Inc [ ONCS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CFO
(Last)          (First)          (Middle)

5820 NANCY RIDGE DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/14/2016
(Street)

SAN DIEGO,, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (right to buy)   (1) $6.12   12/14/2016     D         150000      (2) 7/6/2025   Common Stock   150000     (3) 0   D    
Employee Stock Option (right to buy)   (4) $5.76   12/14/2016     D         75000      (5) 8/21/2025   Common Stock   75000     (3) 0   D    
Employee Stock Option (right to buy)   (4) $1.29   12/14/2016     A      112500         (6) 12/14/2026   Common Stock   112500     (3) 112500   D    

Explanation of Responses:
( 1)  These stock options were granted as Non-qualified stock options.
( 2)  These stock options are scheduled to fully vest on July 6, 2018, the third anniversary of the grant date.
( 3)  On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 150000 shares (previously granted on July 6, 2015) and 75000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 112500 shares of common stock with an exercise price of $1.29 per share.
( 4)  These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option.
( 5)  These stock options are scheduled to fully vest on August 21, 2018, the third anniversary of the grant date.
( 6)  The stock options granted on December 14, 2016 will vest on the following schedule: 25% on grant date; 1/36th of the remaining 75% vesting on each of the 36 subsequent monthly anniversaries of the grant date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SLANSKY RICHARD B
5820 NANCY RIDGE DRIVE
SAN DIEGO,, CA 92121

CFO

Signatures
/s/ Richard B. Slansky 12/16/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to May 2024 Click Here for more OncoSec Medical Charts.
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more OncoSec Medical Charts.